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Abstract: The cys-loop receptor family is a major family of neurotransmitter-operated ion
channels. They play important roles in fast synaptic transmission, controlling neuronal
excitability, and brain function. These receptors are allosteric proteins, in that binding of a
neurotransmitter to its binding site remotely controls the channel function. The cys-loop
receptors also are subject to allosteric modulation by many pharmaceutical agents and
endogenous modulators. By binding to a site of the receptor distinct from the
neurotransmitter binding site, allosteric modulators alter the response of the receptors to
their agonists. The mechanism of allosteric modulation is traditionally believed to be that
allosteric modulators directly change the binding affinity of receptors for their agonists.
More recent studies support the notion that these allosteric modulators are very weak
agonists or antagonists by themselves. They directly alter channel gating, and thus change
the distribution of the receptor across multiple different affinity states, indirectly
influencing receptors’ sensitivity to agonists. There are two major locations of allosteric
modulator binding sites. One is in subunit interfaces of the amino-terminal domain. The
other is in the transmembrane domain close to the channel gating machinery. In this
review, we also give some examples of well characterized allosteric binding pockets.
Keywords: cys-loop receptors; ligand-gated ion channels; allosteric modulator
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1. Introduction
The cys-loop receptor family is a major family of ligand-gated ion channels (LGICs). All members
of this receptor family have a signature cysteine loop, two cysteine residues separated by 13 other
residues, in the amino-terminal domain of each subunit. This family includes subfamilies of nicotinic
receptors (nAChRs) [1], serotonin receptor type 3 (5-HT3R) [2], -aminobutyric acid receptors type A
and C [3–5] (GABAA/CR), glycine receptors [6], zinc-activated cation channel [7], and invertebrate
glutamate/serotonin-activated anionic channels or GABA-gated cation channels [8–10]. Recently,
prokaryotic proton-gated ion channels have also been considered to be in the same family, although
they do not have signature cysteines in the corresponding loop region [11–13]. In eukaryotic ligandgated ion-channels, each receptor subunit has a large amino-terminal extracellular domain, four
transmembrane domains (M1–M4) with the second transmembrane domain (M2) lining the pore, and a
large intracellular loop between M3 and M4 [14,15]. Prokaryotic channels have similar subunit
topology, but with a short M3–M4 intracellular loop. The receptors in this family have a pentameric
structure. That is, five subunits form a pseudo-symmetrical receptor with a central vestibule (Figure 1A).
Different combinations of subunits, and their isoforms, create structural diversity and thus different
subtypes within each cys-loop receptor subfamily. Since each subtype has specialized function, the
structural diversity also provides opportunities for subtype-selective drug development. The
neurotransmitter binding sites (orthosteric sites) are located in the amino-terminal domain at subunit
interfaces [15,16]. Figure 1B shows the crystal structure of nicotine in the binding site of the
homologous protein, acetylcholine binding protein (AChBP) [17]. AChBP is homologous to the
amino-terminal domain of cys-loop receptor’s subunits [18]. It also has a pentameric structure [18] and
can bind nicotinic receptor agonists and antagonists [17,19,20]. Thus, AChBP crystal structures
provide the best structural models for the amino-terminal domain and orthosteric binding sites. In the
center of the transmembrane region of all cys-loop receptors is the ion conducting pore (Figure 1C) [15],
which is controlled by neurotransmitter binding to orthosteric sites in the distal amino-terminal
domain. Thus, the cys-loop receptors are allosteric proteins; binding of a neurotransmitter to the
extracellular amino-terminal domain of its receptor allosterically controls the distantly located
transmembrane ion channel pore, a process termed allosteric activation [21,22]. This allosteric
activation occurs through an evolutionarily conserved allosteric network that connects orthosteric
binding sites to the channel gate [23]. The detailed activation mechanism of cys-loop receptors has
been extensively reviewed recently [21,24–28]. Figure 1D shows the neurotransmitter binding sites
located at subunit interfaces of major subtypes of nicotinic receptors and GABAA/C receptors. A typical
heteromeric receptor (containing at least two different subunits) has two orthosteric binding sites. The
remaining subunit interfaces of the amino-terminal domain of heteromeric receptors can potentially act
as allosteric modulator binding sites. In fact, the well-characterized benzodiazepine binding site in a
typical  GABAA receptor is located in the amino-terminal domain  subunit interface,
homologous to the orthosteric GABA binding sites at the  interfaces (Figure 1D). A typical
homomeric receptor (with identical subunits), such as or nAChR,  GABA receptor,
5-HT3A receptor, or glycine  receptor, has five potential orthosteric binding sites.
The function of the cys-loop receptors can be modified by allosteric modulators. By binding to the
receptor at an allosteric site, a site distinct from the orthosteric neurotransmitter binding sites, allosteric
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modulators alter the agonist sensitivity (shift of concentration-response curve), agonist efficacy
(maximum response), and channel gating kinetics for activation and desensitization. Note the
difference between allosteric activation and allosteric modulation. For allosteric activation, the binding
of neurotransmitter to the “orthosteric” binding site (allosterically) controls the distantly located gating
machinery. However, for allosteric modulation, modulator binding to additional “allosteric” sites
modifies the action of agonists binding to the orthosteric sites. That is, the modulator allosterically
alters the orthosteric agonist’s action We will discuss kinetic models and mechanisms of allosteric
modulation in section 3, and well-characterized allosteric sites in section 4.
Figure 1. Structures of prevalent cys-loop receptors and locations of agonist binding sites.
(A) Top view of the EM structure of the Torpedo nicotinic receptor, generated from 2BG9
PDB file [16], showing pentameric structure; (B) Side view of crystal structure of AChBP
with nicotine bound in the subunit interface, generated from 1UW6 PDB file [17]. The
nicotine is surrounded by residues that form the agonist binding pocket (within blue dashed
circle); (C) Side view of the EM structure of the Torpedo nicotinic receptor with  subunit
removed, revealing central vestibule and channel pore (red arrow), generated from 2BG9
PDB file [16]; (D) Location of agonist binding sites in different subunit interfaces in major
subtypes of nicotinic and GABAA/C receptors. Note that most heteromeric receptors have
two orthosteric agonist binding pockets. In some cases (heteromeric glycine receptor
[29],  nicotinic receptor [30]), functional studies suggest a possible third neurotransmitter
binding site. In addition, the  GABAA receptor has one allosteric benzodiazepine
binding site (BZ).
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2. Kinetic Models of Allosteric Activation
The activation mechanism of the nicotinic receptors can be understood in terms of the MonodWyman-Changeux allosteric activation (MWC) model [8,22,31]. This model can explain the
spontaneous openings observed in the wild type nicotinic receptor [32]. Similarly, activation of the
wild type, and spontaneously-opening gating mutant, GABAA receptors can be well fitted by the MWC
model (Figure 2A).
Figure 2. Kinetic schemes for allosteric activation of a typical heteromeric cys-loop
receptor. (A) Monod-Wyman-Changeux allosteric activation (MWC) model for allosteric
activation [22,33], R, AR, A2R are receptors in the resting states with 0, 1 or 2 agonist
bound. They have low binding affinity (KD). R*, AR*, A2R* are receptors in open states
with high binding affinity (KD*) for agonist; (B) Refined MWC model with intermediate
high affinity flip states F, AF, and A2F [34]. Flip states are pre-open states with increased
affinity for agonists, suggesting a conformational changes in the binding site. Thus, flip
and open states in each oval may be considered “activated” states.

An important feature of this model is that the receptor has low affinity (KD) resting closed states and
high affinity (KD*) open states [22,33]. Binding of the receptor to its agonist facilitates transitions from
low affinity states to high affinity states. This model can explain how mutations in the channel gate
make the receptor more sensitive to agonist. That is, loosening the channel gate would increase
spontaneous openings, resulting in more receptors in the high affinity states, and thus increasing
sensitivity of the receptor to agonists. This mutational effect is similar to the effects of positive
allosteric modulators (see below). The MWC model was further refined by the finding that partial and
full agonist-induced openings have similar opening and closing rates, but with a major difference in
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equilibrium distribution between resting state and “flipped” state, a pre-opening intermediate state with
higher affinity. For a full agonist, the equilibrium constant for flipping is large, so that most fully
liganded receptors will shift to the flip state. For a partial agonist, the equilibrium constant is small, so
that a smaller fraction of fully-liganded receptors will transit to the flip state. However, once the
receptor transitions to a flipped state, full and partial agonists will gate the channel similarly. Thus,
there is a high affinity “flip” state between low affinity resting state and high affinity open state
(Figure 2B;[34]). The pre-opening flip state is an agonist-induced conformational state preceding
channel opening. In this sense, the flip state and open state of the receptor could be collectively
considered as “activated states” (as enclosed in the dashed ovals in Figure 2B). Note that in the kinetic
scheme of Figure 2B, there is no connection between open states. This is because association to, and
dissociation from, the open states are rare events, and adding connections between open states does not
produce any detectable improvement in fitting [29]. Thus, agonist association and dissociation rates for
the open states are much smaller than those for binding in the flip state or resting state. The molecular
basis for the scarcity of transitions between open states is still not clear. One possible explanation is
that the open states could have even higher affinity than the flip states, so that further binding pocket
closure would limit association and dissociation. Detailed descriptions of the evolving kinetic and
activation mechanism models can be found in several recent review papers [21,24–27].
In summary, kinetic studies revealed that binding and gating are coupled, with mutual influence.
The receptor’s affinity for agonists is state dependent. Alteration of the receptor distribution across
different conformational states, either by mutation or by allosteric modulator binding, alters the
distribution of receptors across different agonist affinity states. These alterations change the apparent
affinity of the receptor for its agonists. This concept forms the foundation of allosteric modulation.
3. Kinetic Models and Mechanisms of Allosteric Modulation
For the mechanism of allosteric modulator action, it has long been believed that binding of
allosteric modulators to the receptor directly changes receptor affinity for its agonist. In this model, the
allosteric modulator does not have an intrinsic ability to open the channel. However, this view has
been changed by the observation that the benzodiazepine allosteric agonist, diazepam, can directly
activate the wild type GABAA receptor (with very low efficacy). This effect is only visible when the
receptor is highly expressed in Xenopus oocytes [35]. The super-high expression of the wild type
GABAA receptor also makes it possible to observe spontaneous opening, allowing for testing of the
direct action of GABAA receptor negative allosteric modulators. In fact, the benzodiazepine inverse
agonist methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate (DMCM) can inhibit the measurable
current formed by spontaneous opening of highly expressed wild type GABAA receptors. These small
fractional changes in channel opening induced by positive or negative allosteric modulators can
account for the alteration of the receptor sensitivity to agonist according to the MWC allosteric
activation mechanism [35]. A similar direct gating mechanism, termed allosteric coagonism, was also
proposed for the mechanism of benzodiazepine action. This view is supported by the observation of
direct activation and inhibition of a mutant GABAA receptor by benzodiazepine agonists and inverse
agonists [36]. By making concatenated subunits and selectively destroying one orthosteric binding site,
Baur and Sigel found that the benzodiazepine allosteric potentiator diazepam can facilitate channel
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opening when the receptor has only one orthosteric binding site [37]. This finding also supports the
view that allosteric modulators facilitate channel gating, and that apparent agonist affinity changes are
due to this gating effect. Normally, in the resting unbound state, GABAA receptors have very low open
probabilities (10−4–10−5) [33,36]. The receptor with a single agonist bound will have an open
probability increase of ~700 fold [33]. However, the open probability of a singly bound receptor is still
very low. Binding of a positive allosteric modulator to the receptor will further increase open
probability as observed by Baur and Sigel. The kinetic model in Figure 3 represents an expanded
MWC model that includes direct gating effects of GABAA receptors by a modulator [35]. In this
model, direct gating by a positive allosteric modulator also increases the agonist binding affinity. In
fact, the benzodiazepine agonist flurazepam can induce structural changes in the orthosteric GABA
binding pocket, further supporting a direct gating mechanism for allosteric modulators [38].
Figure 3. Kinetic scheme for allosteric activation and modulation mechanisms (adapted
from [35]). Front is the conventional MWC model. The only difference is that KDA and
KDA* are used to represent agonist binding affinity. Allosteric modulator (M) bound states
are shown at the back of the figure, with KDM and KDM* describing two different affinities
for the modulator in resting or activated states. L is the ratio between R and R*. c is the
ratio between KDA* and KDA. d is the ratio between KDM and KDM*.

This co-activation mechanism of GABAARs by benzodiazepines seems to be applicable to other
allosteric modulators acting on different sites. For example, the general anesthetic etomidate
potentiates GABAA receptor agonist responses at low concentrations, but directly activates the GABAA
receptor at high concentrations. At the same time, high concentration etomidate also further shifts the
GABA concentration-response curve to the left. Both potentiation and activation effects can be well
described by a single MWC kinetic model [39], similar to that for benzodiazepines. Affinity labeling
has identified the binding site of etomidate in the transmembrane domain (Met236 in the M1 domain
of  subunit and Met286 in M3 domain of  subunit) [40]. The allosteric effect of etomidate can be
mimicked by two substitutions at these sites with the bulky residue tryptophan [41]. In contrast, the
benzodiazepine binding pocket is located in the amino-terminal domain (see section 4.1). Thus,
regardless the location of the binding site, in the amino-terminal domain distant from the channel gate
or in the transmembrane domain close to the channel gate, the binding of allosteric modulators to their
sites alters the channel gating. Positive allosteric modulators reduce the gating energy barrier to
facilitate channel opening, serving as weak co-agonists (binding to a site that is distinct from the
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orthosteric neurotransmitter binding site). Conversely, negative allosteric modulators increase the
gating energy barrier to inhibit channel opening. For example, 1 GABAC receptor function can be
inhibited by several neurosteroids [42]. These neurosteroids inhibit the GABAC receptor allosterically
as suggested by monitoring conformational changes with site-specific fluorescence techniques [43].
However, the mechanisms of GABAC receptor inhibition by individual neurosteroids are not the same.
Functional inhibition by -estradiol is correlated to the inhibition of the GABA-induced fluorescence
changes in multiple locations of the amino-terminal domain, including at K217C in loop F, L166C in
loop E, and L66C away from the binding loops, [43]. This suggests that -estradiol can antagonize
GABA-induced conformational changes. In contrast, pregnanolone, pregnanolone sulfate, allopregnanolone sulfate, and tetrahydrodeoxycorticosterone influence GABA-induced fluorescence
changes differently, suggesting distinct detailed structural mechanisms [43]. Note that some
competitive antagonists could be very weak agonists or inverse agonists. However, since they compete
with agonist for the same binding site, their modulatory effect on the agonist response could only be
seen at very low concentrations when the agonist concentration is also very low, with low probability
of mutual competition. In any case, since these competitive antagonists compete with agonists for the
same orthosteric binding site, they are not allosteric modulators.
Since nicotinic receptors have an allosteric activation mechanism similar to that for GABAA
receptor [22], they likely have a similar allosteric modulation mechanism. In fact, the allosteric
modulator PNU-120596 for α7 nicotinic receptor has its binding site in the transmembrane domain
[44] (see Section 4.2 for details), but it can induce a similar, though not identical, conformational
change along the activation pathway as acetylcholine-induced conformational changes during channel
activation [45]. Similarly, allosteric modulation by divalent cations of nicotinic receptors involves
conformational changes in the amino-terminal domain, partially shared with agonist-induced
conformational changes [46]. These experimental observations further support a co-agonist action for
positive allosteric modulators in nicotinic receptors.
In glycine and GABA receptors, alcohol size cut-off (see Section 4.2 for a fuller explanation) is
related to the size of the sidechain of two residues in the transmembrane domains (M2 and M3, see
Section 4.2 for details), suggesting a transmembrane location of their binding site. However, the
structure of loop 2 from the amino-terminal domain, which plays an important role in coupling agonist
binding and channel gating, is also critical for ethanol’s effect [47,48]. Whether loop 2 and its
surrounding residues form a second binding site for ethanol is still not clear. Ethanol’s modulatory
effect on glycine receptor can also be influenced by a third site within the intracellular loop between
M3 and M4, which modifies ethanol’s effect by interacting with G protein subunits [49]. Thus, it is
likely that the allosteric modulation of receptor function by ethanol is through co-agonism with ethanol
binding to one site in the M2 and M3 domains, and that this co-agonist effect can itself be allosterically
modulated by other allosteric modulators, such as G protein interacting with the M3–M4 site, or by
mutations of important residues along the activation pathway, such as in loop 2.
In summary, several lines of evidence suggest that allosteric modulation of cys-loop receptor
function is mediated mainly through a weak direct gating effect by allosteric modulators.
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4. Binding Sites for Allosteric Modulators
As just described, allosteric modulators of cys-loop receptors can bind in two major locations. The
first location is at subunit interfaces of the amino-terminal domain, homologous to the orthosteric
agonist binding sites, but at a different subunit interface. Benzodiazepine agonists, partial agonists,
antagonists, partial inverse agonists, and inverse agonists bind to sites in this category. We will
describe the amino-terminal binding sites for allosteric modulators in Section 4.1. The second major
location of allosteric modulator binding sites is in the transmembrane domain near the channel gate.
Barbiturates, neurosteroids, alcohols and general anesthetics bind to sites of this type. We will describe
the transmembrane binding sites with several examples in Section 4.2. Noncompetitive antagonists
also bind to the transmembrane domain. Some of them have binding sites within the pore. Thus,
binding of these antagonists will occlude the channel pore. The effects of these channel blockers are
usually use-dependent. That is, the binding site is only accessible in the open state. Other
noncompetitive antagonists allosterically inhibit channel activity. It is also possible that a single
antagonist can block the pore, and simultaneously allosterically inhibit channel function. This may
explain a small shift in concentration-response curve sometimes observed in the presence of
noncompetitive antagonist. Picrotoxin is an example of a pore blocker, although the mechanism of its
non-competitive antagonism is still not fully understood. Three studies suggest that it can actively
antagonize conformational changes induced by GABA in the amino-terminal domain; suggesting that,
in addition to blocking the pore, picrotoxin also negatively modulates channel gating and facilitates
channel closing [43,50,51].
In addition to these two major binding sites, residues in the coupling region between the agonist
binding site and the channel domains may also be involved in mediating allosteric modulation. For
example, mutations of the Gly219 residue in the pre-M1 region of the GABAA receptor  subunit can
abolish the effect of several allosteric modulators, such as barbiturates, alphaxalone, etomidate and
propofol [52]. The pre-M1 residue Arg246 of the 5-HT3A receptor is also an important determinant
for allosteric modulation [53]. Another example is that the zinc modulation of GABAA receptors
involves two charged residues located in the cys-loop region [54] that plays an important role in
coupling the amino-terminal domain to the channel gate [55,56].
4.1. Amino terminal binding sites for allosteric modulators
Since most heteromeric cys-loop receptors have only two orthosteric binding sites for agonists,
there is a lot of potential for future drug development in the remaining subunit interfaces that do not
bind conventional agonists. The best-characterized example of an allosteric site in amino-terminal
domain is the benzodiazepine binding pocket of GABAA receptors. It is located in the  subunit
interface, homologous to the GABA binding site in the  subunit interface (Figure 1D). The
benzodiazepine binding pocket is formed by residues in six binding loops, designated as loops A
through F, and homologous to those that form the orthosteric binding pockets. Residues (with rat 1
subunit numbering) identified from Loops A (His101 [57,58], B (Tyr159 [59]), and C (Gly200 [60],
Thr206, and Tyr209 [59,61]) are contributed by the  subunit and form the principal face of the
binding pocket. Residues in loops D (Phe77 [62,63], Ala79, Thr81 [64,65]), E (Met130 [63,66]), and F
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(Glu189, Thr193, and Arg194 [67]) are contributed by  subunit and form the complementary face of
the binding pocket (Figure 4).
For nicotinic receptors, a recent study shows that there is an amino-terminal noncanonical allosteric
site for the positive allosteric modulator morantel in the  subtype [68]. This binding site for the
allosteric modulator is located in the  subunit interface (Figure 4), in contrast to the  interface
for the ACh binding site (Figure 1D). Note that binding residues identified for morantel are located
what is equivalent to the upper half of the homologous orthosteric binding pocket.
Figure 4. Allosteric modulator binding sites (shown as residues with side-chains
displayed) mapped on to the homologous sites of the EM structure of Torpedo nicotinic
receptor  (right) and  (left) subunits (made from 2BG9 PDB file [16]). A wide range of
binding sites for different allosteric modulators are color-coded: Yellow: benzodiazepine
sites; Pink: morantel sites; Red: endogenous neurosteroid sites; Green: etomidate sites;
Dark green: volatile anesthetic site; Blue: PNU-120596 site for  nicotinic receptor;
Cyan: overlapped sites in M2 or M3 domains shared by multiple modulators; Grey:
divalent cation sites; Burgundy: pre-M1 residues that influence anesthetic modulation in
GABAA receptor or 5-HT3 receptor; Note that if a binding site residue is located within a
subunit, then the residue is mapped to the  subunit (right). If a binding pocket is in
subunit interface (involving both subunits), then the residues are mapped to the positions in
 or  subunits, so that they are facing to the same subunit interface. The G protein binding
site in the GlyR intracellular loop is not shown, since much of the intracellular loop
structure is undefined in the EM structure used to create this illustration..
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4.2. Transmembrane domain binding sites for allosteric modulators
The transmembrane domain is the channel forming domain, which includes gating machinery to
control channel opening and closing. Several classes of allosteric modulators have their binding
pockets in the transmembrane domain. These include ethanol and other short-chain alcohols,
neurosteroids, barbiturates, general anesthetics, and some  nAChR positive allosteric modulators
(described more-fully later). A general feature of this type of modulation is that the modulators bind to
a cavity near the channel pore-lining domain, M2, and more directly influence channel gating. The
following are some examples of allosteric modulator binding sites in this category.
Binding of alcohol and volatile anesthetics to the receptor has a cutoff phenomenon. That is, the
allosteric effect is dependent on the size of these compounds. When the size of the compounds
increases above a certain level, the allosteric effect either decreases or is abolished. This cutoff
phenomenon suggests that the receptor has a cavity with a defined volume to accommodate this type of
allosteric modulator. For example, using three volatile anesthetics combined with site-directed
mutagenesis at the 232, 270 and 279 positions of human GABAA receptor  subunit to residues with
different sizes, Jenkins et al. estimated the size of the binding cavity for these anesthetics as between
250 and 370 Å3 in the wild type GABAA receptor [69]. Thus, the residues Leu232 (M1), Ser270 (M2,
15’ position), and Ala291 (M3, homologous to Met286) in the subunit play an important role in
defining the binding cavity for these small molecules. For the alcohol cutoff, the effect of an alcohol is
dependent on the length of its carbon chain. When the carbon chain of an alcohol exceeds a given
length, its effect will decrease. The cutoff value for the carbon chain length of alcohols varies with
different receptors. For example, the homomeric  glycine receptor has an alcohol cutoff value of 10,
whereas the homomeric  GABA receptor has a cutoff value of 7. Using chimeras of glycine and
GABA receptors, Wick et al. identified two critical residues in M2 and M3 domains as the main
determinants of the observed difference in cutoff [70]. These two residues are Ser267 (M2, 15’
position) and Ala288 (M3) in the glycine receptor  subunit. The homologous residues in the 
GABA receptor are Ile307 (M2) and Trp328 (M3, homologous to Met286). Mutation at Ser267 of
the glycine receptor 1 subunit to a larger sized residue decreases the cutoff, whereas mutations of
Ile307 and Trp328 in the  GABA receptor subunit to smaller residues increases the cutoff,
supporting the concept of a defined cavity between M2 and M3 domains for alcohol binding.
Non-volatile general anesthetics, such as etomidate, propofol and barbiturates are mainly positive
allosteric modulators of GABAA receptors, although they can inhibit nicotinic receptors and influence
other channel function [71]. The binding sites of these allosteric modulators are also located in the
transmembrane domain. In GABAA receptors, the etomidate binding site was identified by
photoaffinity labeling [Met236 (M1), Met286 (M3)] [40] and by a mutagenesis study
[Asn265 (M2, 15’ position)] [72]. The M3 binding site Met286 is shared with propofol [73],
whereas M2 residue Asn265 is homologous to Leu270 of the 5-HT3 receptor, which is also
responsible for volatile anesthetic action [74]. ([H3]azi)Etomidate photoaffinity labeling of Met236
(M1) &Met286 (M3) can be directly competed by volatile anesthetic isoflurane [75], suggesting
they share the binding site. However, ([H3]azi) etomidate photoaffinity labeling is allosterically
inhibited by barbiturates and propofol [75], and allosterically enhanced by neurosteroids [76],
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suggesting these allosteric modulators can directly induce conformational changes in the
transmembrane domains of the receptor and thus alter the binding of other allosteric modulators.
Neuroactive steroids, termed neurosteroids, include steroid hormones, their metabolites, and synthetic
steroid anesthetics. In addition to genomic effects (regulating gene expression), many steroid hormones
and their metabolites have non-genomic effects, including allosteric modulation of ligand-gated ion
channel function. Naturally occurring neurosteroids are endogenous regulators of GABAA receptors [77].
A good example of non-genomic neurosteroid effects is positive allosteric modulation of GABAA
receptors by the endogenous neurosteroids allopregnanolone and tetrahydrodeoxycorticosterone
(THDOC). At low concentrations, they potentiate GABA effects, whereas at high concentrations, they
directly activate GABAA receptors. These two different effects are mediated by binding of the
neurosteroids to two different binding sites in the transmembrane domain [78]. The potentiation site is
located within the transmembrane domain of the  subunit, formed by residues Gln241 (M1), Asn407
(M4), and Tyr410 (M4). In contrast, the activation site is located at the subunit interface of the
transmembrane domains between  and  subunits, formed by Tyr284 (M3) and Thr236 (M1).
Neurosteroids also modulate nicotinic receptors. However, they are not well characterized in this context.
Compared to GABA receptors, development of nicotinic receptor allosteric modulators is more
recent. Positive allosteric modulators for the  nAChR are the best-developed examples of nicotinic
receptor modulators. nAChR has fast desensitization kinetics. Positive allosteric modulators
(PAMs) for  nAChR can be classified into two types: type I and type II, according to their influence
on current kinetics. Type I PAMs mainly potentiate current without significantly influencing receptor
desensitization. Ivermectin [79], 5-hydroxyindole (5-HI) [80], genistein [81], compound 6 [82], and
NS-1738 [83] are examples of type I PAMs. 5-hydroxyindole is also an allosteric modulator for
serotonin receptor type 3. The binding site of 5-HI in 5-HT3A receptor is located at Leu293 of the M2
domain [84]. In contrast, type II PAMs can dramatically reduce desensitization or even re-activate
desensitized receptors. PNU-120596 is the best-characterized representative of this type [85]. Its
binding pocket is located in the transmembrane domain [44], and is formed by five residues: Ser222
(M1), Ala225 (M1), Met253 (M2, 15’ position), Phe455 (M4), and Cys459 (M4). Each 7 subunit
harbors one such site.
Other allosteric modulators: In addition to small drug compounds, cys-loop receptors can be
allosterically modulated by divalent cations, such as zinc and calcium, and some small peptides. For
example, zinc can inhibit GABAA [86] and GABAC receptors [87]. Calcium can modulate nicotinic
receptor desensitization kinetics [88]. Secreted mammalian Ly-6/uPAR-related protein 1 (SLURP-1) is
also a potentiator of 7 nicotinic receptors [89]. Small peptide allosteric modulators of glycine
receptors can be selected from a peptide phage-display library [90]. The zinc binding sites for zinc
modulation of GABAA receptors have been identified as five charged residues in three locations of the
receptor. They are Glu137 (pre-cys-loop), His141 (cys-loop), Glu182 (loop F), His267 (M2,
17’ position), Glu270 (M2, 20’ position) [54]. Similar sites in the  subunit are responsible for the
high sensitivity of the  GABAA receptor to zinc potentiation [91]. The calcium binding sites in
 nAChR are at Glu172 of loop F, homologous to the zinc binding site in the  GABA receptor
subunit (Glu182), and Glu44 of loop 2 [92, 93].
In summary, the mechanism of action for all allosteric modulators of cys-loop proteins is likely to
involve altering channel gating. The alteration of channel gating will influence the distribution of
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receptors across different affinity states. The net observable effects are changes in the receptor
maximal current, gating kinetics, and sensitivity to agonist. All these changes can be explained by a
single MWC-type allosteric model. There are two major binding site locations for allosteric
modulators: at amino-terminal domain subunit interfaces and the transmembrane domain. However,
other locations along the activation pathway, especially the coupling region between amino-terminal
domain and transmembrane domain, or even the intracellular loop, could be potential sites for novel
allosteric modulator development. In fact, G protein βγ can modify glycine receptor function by
interacting with two basic motifs in the beginning and the end of the M3−M4 intracellular loop [94].
The positively charged residues in these two motifs, along with the Gβγ protein, are also critical for the
action of ethanol on the glycine receptor [49]. Figure 4 summarizes the binding sites discussed above,
mapped onto the 3-D EM structure of Torpedo nicotinic receptor  and  subunits [16].
GABAA receptor allosteric modulators are relatively well characterized and developed. A recent
research trend is to develop novel allosteric modulators with subtype specificity in other members of
the cys-loop family, especially nicotinic receptors. Another important development is negative
allosteric modulators of GABAA receptors. Development of GABAA receptor negative allosteric
modulators was hampered by their non-selectivity between different receptor subtypes, resulting in
increased seizure susceptibility. However, recent development of more subtype selective negative
allosteric modulators shows promising results. For example,  subunit containing GABAA receptors
are mainly distributed in the hippocampus, and  selective inverse agonists (negative allosteric
modulators) can improve cognitive function [95,96]. We expect more subtype specific allosteric
modulators for cys-loop receptors will be developed in the near future.
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